PM
PME.AU Pro Medicus Ltd
- Market cap
- AUD 20.5B
- P/E
- 77.2x
- P/B
- 45.46x
- ROE
- 58.8%
- Dividend yield
- 0.32%
- Fundamental score
- 3.8/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PME.AU undervalued?
Graham numberThe Graham number of Pro Medicus Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pro Medicus Ltd fundamental analysis
16 of 22 checks passedROE 2/2
High return on equity (58.8%), above 20%.
ROA 1/1
Return on assets (43.5%) is above the industry median (-45.6%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (130.3%) is above the 5-year average (53.8% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (130.3%) is above the industry median (18.9%).
Revenue Growth 2/2
Revenue grew 28.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (0.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (77.2x) is above the market median (15.0x).
PE vs Industry 0/1
PE (77.2x) is above the industry median (11.1x).
PBV 0/1
Price to book (45.5x) is above the industry median (5.7x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 3,511.2, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.44, above 1.
Dividend Yield 0/2
Dividend yield (0.3%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 24.4%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Pro Medicus Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pro Medicus Ltd
Pro Medicus Limited, a healthcare informatics company, provides medical imaging software and services to hospitals, imaging centers, and health care groups in Australia, Europe, and North America. The company offers Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, typing, HL7 integration, financial reporting, picture archive and communication system (PACS) integration, digital dictation, and voice recognition integra…
Full company profilePro Medicus Ltd financial statements
Pro Medicus Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 31.6M | 35.9M | 50.1M | 56.8M | 67.9M | 93.5M | 125M | 161M | 213M | 262M |
| Gross Profit | 31.1M | 35.7M | 48.7M | 56.4M | 46.7M | 92.9M | 92.4M | 122M | 213M | 211M |
| Operating Income | 15.0M | 14.8M | 25.5M | 30.1M | 42.4M | 62.4M | 83.9M | 112M | 158M | 196M |
| EBITDA | 18.4M | 21.8M | 31.5M | 37.7M | 49.5M | 69.6M | 91.7M | 121M | 165M | 204M |
| Net Income | 9.32M | 9.97M | 19.1M | 23.1M | 30.9M | 44.4M | 60.6M | 82.8M | 115M | 265M |
| EPS | 0.09 | 0.10 | 0.18 | 0.22 | 0.29 | 0.42 | 0.58 | 0.79 | 1.10 | 2.54 |
| Balance Sheet | ||||||||||
| Total Assets | 47.2M | 61.0M | 84.3M | 95.6M | 126M | 157M | 202M | 257M | 339M | 610M |
| Total Liabilities | 12.4M | 26.0M | 35.0M | 35.5M | 43.9M | 55.3M | 63.4M | 69.7M | 81.7M | 159M |
| Shareholders' Equity | 34.8M | 35.1M | 49.3M | 60.2M | 81.7M | 102M | 139M | 188M | 257M | 451M |
| Cash & Short-term Investments | 22.8M | 25.2M | 32.3M | 43.4M | 61.8M | 90.6M | 121M | 155M | 209M | 251M |
| Total Debt | - | - | 7.63M | 2.28M | 2.62M | 2.28M | 1.85M | 2.07M | 2.26M | 2.23M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 14.8M | 13.9M | 24.7M | 31.4M | 38.8M | 61.6M | 62.5M | 86.8M | 111M | 127M |
| Capital Expenditure | 80.0K | 219K | 342K | 7.87M | 7.69M | 9.02M | 6.45M | 6.69M | 7.38M | 8.69M |
| Free Cash Flow | 14.7M | 13.7M | 24.3M | 23.5M | 31.1M | 52.6M | 56.1M | 80.1M | 104M | 119M |
| Ratios | ||||||||||
| ROE | 26.8% | 28.4% | 38.8% | 38.3% | 37.8% | 43.7% | 43.7% | 44.1% | 44.8% | 58.8% |
| ROA | 19.7% | 16.3% | 22.7% | 24.1% | 24.6% | 28.3% | 30.0% | 32.2% | 34.0% | 43.5% |
| Net Profit Margin | 29.5% | 27.7% | 38.2% | 40.6% | 45.4% | 47.6% | 48.6% | 51.3% | 54.1% | 101.4% |
| Debt to Equity | - | - | 0.15x | 0.04x | 0.03x | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pro Medicus Ltd dividends
- Dividend yield
- 0.32%
- Forward dividend
- 0.69 AUD
- Payout ratio
- 24.4%
- Ex-dividend date
- Sep 7, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 64.8M | 0.62 | 24.4% |
| 2025 | AUD 49.1M | 0.47 | 42.6% |
| 2024 | AUD 36.6M | 0.35 | 44.2% |
| 2023 | AUD 26.1M | 0.25 | 43.0% |
| 2022 | AUD 18.8M | 0.18 | 42.3% |
| 2021 | AUD 13.5M | 0.13 | 43.9% |
| 2020 | AUD 10.9M | 0.10 | 47.3% |
| 2019 | AUD 9.84M | 0.09 | 51.5% |
| 2018 | AUD 5.15M | 0.05 | 51.7% |
| 2017 | AUD 3.08M | 0.03 | 33.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Pro Medicus Ltd
- Insiders 48.96%
- Institutions 25.20%
- Public & others 25.84%
- Shares outstanding 104M
- Free float 53.3M
Top funds holding PME.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Goldman Sachs International Small Cap Insights Fund | 771K | 0.74% | - | Jan 2021 |
| Vanguard International Stock Index-Total Intl Stock Indx | 708K | 0.68% | - | Oct 2020 |
| Aberdeen Standard SICAV I-Asian Smaller Companies Fd | 445K | 0.43% | - | Feb 2021 |
| Wasatch International Opportunities Fund | 397K | 0.38% | - | Dec 2020 |
| Brinker Capital Destinations Tr-Destinations International Equity Fd | 305K | 0.29% | - | Nov 2020 |
| DFA Asia Pacific Small Company Series | 300K | 0.29% | - | Jan 2021 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 265K | 0.25% | - | Dec 2020 |
| Global X Fds-Global X Telemedicine & Digital Health ETF | 263K | 0.25% | - | Feb 2021 |
| iShares Core MSCI EAFE ETF | 234K | 0.22% | - | Feb 2021 |
| iShares MSCI EAFE Small Cap ETF | 205K | 0.20% | - | Feb 2021 |
Pro Medicus Ltd company profile
- Company name
- Pro Medicus Ltd
- Ticker
- PME.AU
- ISIN
- AU000000PME8
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 153
- Fiscal year end
- June
- Address
- 450 Swan Street, Richmond, VIC, Australia, 3121
- Phone
- 61 3 9429 8800
- Website
- promed.com.au
About Pro Medicus Ltd
Pro Medicus Limited, a healthcare informatics company, provides medical imaging software and services to hospitals, imaging centers, and health care groups in Australia, Europe, and North America. The company offers Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, typing, HL7 integration, financial reporting, picture archive and communication system (PACS) integration, digital dictation, and voice recognition integration; and Visage RIS/PACS, a solution for imaging needs of organizations. It also provides Visage 7 Enterprise Imaging Platform, a healthcare imaging software for radiologists, physicians, and clinicians for access and visualization capability comprising rapidly viewing 2-D, 3-D, and 4-D medical images, as well as PACS, digital imaging software, training, installation, and professional services and support products; and Visage Ease, a native mobile application for access to medical imaging results stored on a Visage 7 server from iOS devices, including iPad, iPhone, and iTouch. In addition, the company offers Visage Ease Pro for interpreting diagnostic imaging studies; and Promedicus.net, an e-health offering. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Pro Medicus Ltd management
10- Dr. Sam Aaron Hupert M.B.B.S., M.D.Co-Founder, CEO, MD & Executive Director
- Mr. Anthony Barry Hall B.Sc., B.Sc.(Hons), M.Sc.Co-Founder, Technology Director & Executive Director
- Ms. Danny English C.A.Chief Financial Officer & Company Secretary
- Dr. Malte Westerhoff Ph.D.GM of Europe & Global CTO
- Mr. Garry SherriffHead of Investor Relations
- Mr. Brad LevinGM of North America & Global Head of Marketing
- Ms. Sharni L. RedenbachPeople & Culture Director
- Mr. Sean Michael LambrightGlobal Head of Sales - Visage Imaging Inc
- Ms. Teresa GschwindGlobal Head of Customer Service of Visage Imaging Inc.
- Mr. Tim KernChief Strategy Officer